For nearly 20 years, Jazz has been at the forefront of pioneering innovative medicines for rare, hard-to-treat disorders. Jazz has launched Pioneering Pathways to showcase the people, and pioneering research, behind Jazz’s unique scientific approach. Watch the inaugural episode that focuses on idiopathic hypersomnia and features perspectives from across the community.
To address the low understanding of idiopathic hypersomnia (IH), Jazz partnered with the Hypersomnia Foundation to launch I Have IH, a disease awareness campaign aimed at increasing knowledge of IH. In a previous Our Stories article, we focused on results from the patient and supporter surveys that unveiled the difficult and prolonged diagnosis journey people with IH and their supporters often endure. In this piece, we focus on additional results from the surveys that show the debilitating effects IH has on day-to-day life.
Idiopathic hypersomnia (IH) is a debilitating neurologic sleep disorder that is not common or widely understood. To address this lack of knowledge around the condition, Jazz partnered with the Hypersomnia Foundation to launch I Have IH, an awareness campaign highlighting physician, patient and supporter perspectives to better understand the level of knowledge of IH and its real-life impact on those living with the disorder.
Receiving a diagnosis of any kind has implications not just for the person on the receiving end, but also for their family, friends and the people closest to them. As part of our commitment to patients and their care teams, this National Family Caregivers Month, we shine a light on this essential role and its many nuances.
During National Family Caregivers Month, we recognize and honor family caregivers who dedicate time and resources to caring for their loved ones. Jazz is committed to raising awareness of the essential role that caregivers play and the challenges they face, and to educating communities on ways to increase support for them.
Living an adventurous life at the age of 22, Caroline thought she was pursuing her dream. At the time, she was living in Korea, where she was teaching elementary school and applying for her Ph.D. after completing a bachelor’s degree in Immunology from the University of Edinburgh. She never would have suspected that what she thought was just a regular cold, maybe caught from her young students, would ultimately lead to a life-changing and potentially life-threatening diagnosis.
Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments.
Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.
As a long-time leader in neuroscience, Jazz has held a longstanding commitment to provide therapies and support for patients living with serious, debilitating neurologic disorders, to help them reclaim their lives. Even though essential tremor (ET) is considered the most common movement disorder, affecting millions of people worldwide,1 there are limited treatment options for patients.
As a leader in sleep medicine, Jazz’s nearly 20-year leadership has been built around tackling rare sleep conditions, all while centering on and giving a voice to the patient and caregiver experiences, such as those living with idiopathic hypersomnia. Read more about our plans to expand and spotlight the I Have IH awareness campaign at SLEEP 2023.
For nearly 20 years, Jazz Pharmaceuticals has been a leader in sleep medicine. At SLEEP 2023, we reflect on our key learnings from the past two decades and reaffirm our longstanding commitment to the sleep community.
As both ASCO and SLEEP kick off this weekend, we are excited to meet with thought leaders and advocates across the oncology and sleep communities. By applying our pioneering approach and deep expertise in sleep disorders and oncology, we are working hard to advance industry-leading research and development so we can deliver new potential therapies to help even more patients.
